Counterfeit medicines
relevance, consequences and strategies to combat the global crisis
DOI:
https://doi.org/10.1590/s2175-97902023e20402Keywords:
Counterfeit medicines, Falsification, Legislation, Medicines supply chain, BrazilAbstract
Counterfeiting of medicines, also known as “falsification” or “adulteration”, is the process in which the identity, origin, or history of genuine medicines are intentionally modified. Currently, counterfeit medicines are a global crisis that affects and is mostly caused by developing countries in Asia, Africa and Latin America. These countries lack strict law enforcement against this practice and have low-income populations with medicinal needs. Lately, the crisis has escalated, impacting developed countries as well, e.g., the US and the EU, mainly via the Internet. Despite this extension, some current laws aim to control and minimize the crisis’ magnitude. Falsification of medicines maintains an illegitimate supply chain that is connected to the legitimate one, both of which are extremely complex, making such falsification difficult to control. Furthermore, political and economic causes are related to the crisis’ hasty growth, causing serious consequences for individuals and public health, as well as for the economy of different countries. Recently, organizations, technologies and initiatives have been created to overcome the situation. Nevertheless, the development of more effective measures that could aggregate all the existing strategies into a large functioning network could help prevent the acquisition of counterfeit medicines and create awareness among the general population.
Downloads
References
Agência Nacional de Vigilância Sanitária - Produtos Irregulares, 2020. [cited 2020 Aug 13] Available from: Available from: http://portal.anvisa.gov.br/produtos-irregulares#/
» http://portal.anvisa.gov.br/produtos-irregulares#/
Ames J, Souza DZ. Falsificação de Medicamentos no Brasil. Rev Saúde Pública. 2012;46(1):154-9.
Armocida B, Formenti B, Ussai S, Palestra F, Missoni E. The Italian health system and the COVID-19 challenge. Lancet Public Health. 2020;S2468-2667(20)30074-8.
Attaran A, Bate R, Kendal M. Why and How to Make an International Crime of Medicine Counterfeiting. J Int Crim Justice. 2011;9(2):325-354.
Bate R, Jensen P, Hess K, Mooney L, Milligan J. Substandard and falsified anti-tuberculosis drugs: a preliminary field analysis. Int J Tuberc Lung Dis. 2013;17(3):308-311.
Blackstone EA, Fuhr JP, Pociask S. The Health and Economic Effects of Counterfeit Drugs. Am Health Drug Benefits. 2014;7(4):216-224.
Biguetti C, Marrelli MT, Brotto M. Primum non nocere - Are chloroquine and hydroxychloroquine safe prophylactic/ treatment options for SARS-CoV-2 (covid-19)? Rev Saude Publica. 2020;54(68)1-5.
Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection A Randomized Clinical Trial. JAMA Netw Open. 2020;3(4)1-14.
Burns W. WHO launches taskforce to fight counterfeit drugs. Bull World Health Organ. 2006;84(9):689-690.
Campbell N, Clark JP, Stecher VJ, Goldstein I. InternetOrdered Viagra (Sildenafil Citrate) Is Rarely Genuine. J Sex Med. 2012;9(9)2943-2951.
Charles MW, 2020. Counterfeit drugs: A major issue for vulnerable citizens throughout the world and in the United States. JAPhA. 2020;1-6.
Chinwendu O. The fight against fake drugs by NAFDAC in Nigeria. [Master’s dissertation] - Amsterdam: Royal Tropical Institute, Vrije Universiteit; 2008.
Conselho Regional de Farmácia de São Paulo, 2012. [cited 2020 Aug 13]. Available from: Available from: http://www.crfsp.org.br/documentos/materiaistecnicos/Combate_Falsificacao_e_Roubo_de_Medicamentos.pdf
Council of Europe, 2015. [cited 2020 Feb 29]. Available from: Available from: https://rm.coe.int/CoERMPublicCommonSearchServices/DisplayDCTMContent?documentId=09000016806a966a
» https://rm.coe.int/CoERMPublicCommonSearchServices/DisplayDCTMContent?documentId=09000016806a966a
Coustasse A, Arvidson C, Rutsohn P. Pharmaceutical Counterfeiting and the RFID Technology Intervention. J Hosp Mark Public Relations. 2010;20(2):100-115
Dégardin K, Roggo Y, Margot P. Forensic intelligence for medicine anti-counterfeiting. Forensic Sci Int. 2015;248:15-32.
Dégardin K, Roggo Y, Margot P. Understanding and fighting the medicine counterfeit market. J Pharm Biomed Anal. 2013;87:167-175.
Delepierre A, Gayot A, Carpentier A. Update on counterfeit antibiotics worldwide; Public health risks. Med Mal Infect. 2012;42(6):247-255.
Fantasia HC, Vooys KM. Public Health Implications of Counterfeit Medications. NWH J. 2018;22(3):264-268.
Gautam CS, Utreja A, Singal GL. Spurious and counterfeit drugs: a growing industry in the developing world. Postgrad Med J. 2009;85(1003):251-256.
Goyanes M. Tópicos em propriedade intelectual: marcas, direitos autorais, designs e pirataria. Rio de Janeiro: RG: Renovar; 2008.
Guastalegname M, Vallone A. Could Chloroquine / Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment? Clin Infect Dis. 2020;71(15):888-889.
Hurtado RL, Lasmar MC. Medicamentos falsificados e contrabandeados no Brasil: panorama geral e perspectivas de combate ao seu consumo. Cad Saúde Pública. 2014;30(4):891895.
Instituto Nacional de Controle de Qualidade em Saúde - Apresentação, Missão, Visão, Valores, 2020. [cited 2020 Aug 13]. Available from: Available from: https://www.incqs.fiocruz.br/index.php?option=com_content&view=article&id=61&Itemid=57
» https://www.incqs.fiocruz.br/index.php?option=com_content&view=article&id=61&Itemid=57
International Police (INTERPOL) News, 2011. [cited 2020 Fev 29]. Available from: Available from: https://www.interpol.int/Newsand-Events/News/2011/Global-operation-strikes-at-onlinesupply-of-illegal-and-counterfeit-medicines-worldwide
International Police (INTERPOL) News, 2013. [cited 2020 Fev 29]. Available from: Available from: https://www.interpol.int/Newsand-Events/News/2013/INTERPOL-and-pharmaceuticalindustry-launch-global-initiative-to-combat-fake-medicines
Jackson G, Arver S, Banks I, Stecher VJ. Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks. Int J Clin Pract. 2010;65(4):497-504.
Kelesidis T, Falagas ME. Substandard/Counterfeit Antimicrobial Drug. Clin Microbiol Rev. 2015;28(2):443-464.
Kelesidis T, Kelesidis I, Rafailidis PI, Falagas ME. Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. J Antimicrob Chemother. 2007;60(2):214-236.
Laboratório Central de Saúde Pública de Santa Catarina Apresentação, 2020. [Cited 2020 Aug 13]. Available from: Available from: http://lacen.saude.sc.gov.br/lacen_apresentacao.php
» http://lacen.saude.sc.gov.br/lacen_apresentacao.php
Lemos DRQ, D’Angelo SM, Farias LABG, Almeida MM, Gomes RG, Pinto GP, et al. Health system collapse 45 days after the detection of COVID-19 in Ceará, Northeast Brazil: a preliminary analysis. Rev Soc Bras Med Trop. 2020;53:(e20200354).
Liang BA. Fade to Black: Importation and Counterfeit Drugs. Am J Law Med. 2006;32:279-323.
Mackey TK, Liang BA. The Global Counterfeit Drug Trade: Patient Safety and Public Health Risks. J Pharm Sci. 2011;100(11):4571-4579.
Mackey TK. Global health diplomacy and the governance of counterfeit medicines: a mapping exercise of institutional approaches. J Health Diplomacy. 2013;1:1-20.
Madhav N, Oppenheim B, Gallivan M, Mulembakani P, Rubin E, Wolfe N. Pandemics: Risks, Impacts, and Mitigation. In Jamison DT, Gelband H, Horton S, Jha P, Laxminarayan R, Mock CN, Nugent R, editors. Disease Control Priorities: Improving Health and Reducing Poverty. 3rd ed. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2018. p.315-347.
Nayyar GML, Breman JG, Herrington JE. The global pandemic of falsified medicines: Laboratory and field innovations and policy perspectives. Am J Trop Med Hyg. 2015;92(6):2-7.
Neto JC, Lisboa FLC. ATR-FTIR characterization of generic brand-named and counterfeit sildenafiland tadalafilbased tablets found on the Brazilian market. Sci Justice. 2017;57(4):283-295.
Newton PN, Amin AA, Bird C, Passmore P, Dukes G, Tomson G, et al. The Primacy of Public Health Considerations in Defining Poor Quality Medicines. PLoS Med. 2011;8(12):1-5.
Newton PN, Green MD, Fernández FM, Day NPJ, White NJ. Counterfeit anti-infective drugs. Lancet Infect Dis. 2006;6(9):602-613.
Organization for Economic Cooperation and Development (OECD). The Economic Impact of Counterfeiting and Piracy. France: OECD publishing; 2008, 397 p. Available from: https://www.oecd-ilibrary.org/trade/the-economic-impactof-counterfeiting-and-piracy_9789264045521-en
» https://www.oecd-ilibrary.org/trade/the-economic-impactof-counterfeiting-and-piracy_9789264045521-en
Pharmaceutical Security Institute - Geographic Distribution, 2019. [cited 2020 Feb 10]. Available from: Available from: https://www.psiinc.org/geographic-distribution
» https://www.psiinc.org/geographic-distribution
Piovesan MF, Labra ME. Institutional change and political decision making in the creation of the Brazilian National Health Surveillance Agency. Cad Saúde Pública 2007;23(6):1373-1382.
Pisani E. WHO Global Surveillance and Monitoring System for Substandard and Falsified Medical Products. Geneva, Switzerland: WHO Press; 2017.
Presidência da República, 2009 (Brasil). Decreto-lei nº11.903, de 14 de janeiro de 2009. Dispõe sobre o rastreamento da produção e do consumo de medicamentos por meio de tecnologia de captura, armazenamento e transmissão eletrônica de dados. Diário Oficial da União 14 jan 2009; Seção 1.
Presidência da República (Brasil). Decreto-lei nº2.848, de 7 de dezembro de 1940. Código Penal. Diário Oficial da União 31 dez 1940; Seção 1.
Presidência da República, 1998a (Brasil). Decreto-lei nº9.677, de 2 de julho de 1998. Altera dispositivos do Capítulo III do Título VIII do Código Penal, incluindo na classificação dos delitos considerados hediondos crimes contra a saúde pública, e dá outras providências. Diário Oficial da União 3 jul 1998a; Seção 1.
Presidência da República, 1998b (Brasil). Decreto-lei nº9.695, de 2 de setembro de 1998. Acrescenta incisos ao art. 1o da Lei no 8.072, de 25 de julho de 1990, que dispõe sobre os crimes hediondos, e altera os arts. 2o, 5o e 10 da Lei no 6.437, de 20 de agosto de 1977, e dá outras providências. Diário Oficial da União 20 ago 1998b; Seção 1.
Reynolds L, Mckee M. Organised crime and the efforts to combat it: a concern for public health. Glob Health. 2010;6(21)1-13.
Shepherd M. Beef up international cooperation on counterfeits. Nat Med. 2010;6(9):366.
Silveira SN. Contrafacção/ Falsificação de Medicamentos. [Master’s dissertation]. Lisboa: Universidade Lusófona de Humanidades e Tecnologias; 2012.
The European Parliament and The Council of The European Union (Europe). Directiva 2011/62/EU, of June 8 2011. Amending Directive 2001/83/EC on the Community code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products. Official Journal of the European Union 8 June 2011; vol. 174
The Global Pharma Health Fund, 2020. [cited 2020 Fev 29]. Available from: Available from: https://www.gphf.org/en/index.htm
» https://www.gphf.org/en/index.htm
The Partnership for SafeMedicines News, 2010. [cited 2020 Feb 29]. Available from: Available from: https://www.safemedicines.org/2010/03/nigeria-using-sms-to-thwart-counterfeit-drugs.html
» https://www.safemedicines.org/2010/03/nigeria-using-sms-to-thwart-counterfeit-drugs.html
The Partnership for SafeMedicines About The Partnership For Safe Medicines, 2020a. [cited 2020 Feb 29]. Available from: Available from: https://www.safemedicines.org/about-us
» https://www.safemedicines.org/about-us
The Partnership for SafeMedicines - SafeMeed Tools, 2020b [cited 2020 Feb 29]. Available from: Available from: https://www.safemedicines.org/safemedstools
» https://www.safemedicines.org/safemedstools
United Nations Office on Drugs and Crime - News, 2013. [cited 2020 Feb 20]. Available from: Available from: http://www.unodc.org/unodc/en/frontpage/2013/February/conference-focuses on-the-role-of-organized-crime-in-the-trafficking-offraudulent-medicines.html?ref=fs4
» http://www.unodc.org/unodc/en/frontpage/2013/February/conference-focuses on-the-role-of-organized-crime-in-the-trafficking-offraudulent-medicines.html?ref=fs4
United States Food and Drug Administration PDMA, 2018a. [cited 2020 Feb 12]. Available from: Available from: https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/prescription-drug-marketing-act-1987
United States Food and Drug Administration DSCSA, 2019a. [cited 2020 Feb 29]. Available from: Available from: https://www.fda.gov/drugs/drug-supply-chain-integrity/drug-supply-chainsecurity-act-dscsa
» https://www.fda.gov/drugs/drug-supply-chain-integrity/drug-supply-chainsecurity-act-dscsa
United States Food and Drug Administration Safety information, 2020. [cited 2020 Feb 29]. Available from: Available from: https://www.fda.gov/safety/medwatch-fda-safety-information-andadverse-event-reporting-program
» https://www.fda.gov/safety/medwatch-fda-safety-information-andadverse-event-reporting-program
United States Food and Drug Administration Counterfeit Medicine, 2019b. [cited 2020 Feb 10]. Available from: Available from: https://www.fda.gov/drugs/buying-using-medicine-safely/counterfeit-medicine
» https://www.fda.gov/drugs/buying-using-medicine-safely/counterfeit-medicine
United States Food and Drug Administration How to Buy Medicines Safely from an Online Pharmacy, 2018b. [cited 2020 Feb 29]. Available from: Available from: https://www.fda.gov/consumers/consumer-updates/how-buy-medicines-safelyonline-pharmacy
» https://www.fda.gov/consumers/consumer-updates/how-buy-medicines-safelyonline-pharmacy
Virella D. Falsificação de medicamentos. Uma realidade à qual é preciso dar atenção. Acta Pediatr Port. 2008; 39(1):46-50.
Wertheimer AI, Norris J. Safeguarding against substandard/ counterfeit drugs: Mitigating a macroeconomic pandemic. Res Soc Adm Pharm. 2009;5(1):4-16.
World Health Organization Regional Office for Europe, 2014. [cited 2020 Feb 25]. Available from: Available from: https://www.euro.who.int/en/health-topics/Health-systems/health-technologiesand-medicines/news/news/2014/06/who-surveillanceand-rapid-alert-system-for-substandardspuriousfalselylabelledfalsifiedcounterfeit-ssffc-medical-products
World Health Organization - International Medical Products Anti-Counterfeiting Taskforce IMPACT: Frequently Questions with Answers, 2010 [cited 2020 Oct 4]. Available from: Available from: https://www.who.int/medicines/services/counterfeit/impact-faqwa.pdf
» https://www.who.int/medicines/services/counterfeit/impact-faqwa.pdf
World Health Organization Substandard and falsified medical products, 2018. [cited 2020 Oct 3]. Available from: Available from: https://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-medical-products
» https://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-medical-products
World Health Organization WHO Coronavirus Disease (COVID-19) Dashboard, 2020a. [cited 2020 Aug 4]. Available from: Available from: https://covid19.who.int/
World Health Organization WHO Global Surveillance and Monitoring System, 2020b. [cited 2020 Aug 3]. Available from: Available from: https://www.who.int/medicines/regulation/ssffc/surveillance/en/
» https://www.who.int/medicines/regulation/ssffc/surveillance/en/
World Health Organization. A study on the public health and socioeconomic impact of Substandard and falsified medical products . Geneva, Switzerland: WHO Press ; 2017.
World Trade Organization (International). Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), Article 51 and Article 61, of 1 January 1995. Suspension of Release by Customs Authorities and Criminal Procedures. WTO legal documents; Annex 1c.
Yadav S, Rawal G. Counterfeit drugs: problem of developing and developed countries. Int J Pharm Chem Anal. 2015;2(1):46-50
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
